Best Life Sciences Companies in Switzerland
The 864 best Life Sciences companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ADC Therapeutics.
Switzerland's Life Sciences sector is one of the more quietly formidable clusters in global biotech, and this page ranks the best Life Sciences companies in Switzerland by disclosed equity funding and recent funding momentum. We're tracking 864 companies with $11.1B in total disclosed funding, one unicorn, and a top tier that moves fast. Windward Bio leads at $365M, MindMaze Therapeutics sits close behind at $361M, and Distalmotion has pulled $240M. That's real capital concentration. The global market context matters here too: Morgan Stanley's recent read on life science tools points to a sector valued around $167.8B growing at roughly 10.2% CAGR, driven by an aging population and sustained institutional funding flows.
So what's actually hot right now? Coverage breadth is flat, but the themes drawing capital are specific: stem cell banking, cell-based therapies, diagnostic biotechnology, and gene delivery systems. And if you want a signal on where digital health meets life sciences, median app install growth across healthcare and life sciences platforms is running at roughly +43% YoY. That's not noise. Investors like Venture Kick, EIC Fund, and MassChallenge are the names showing up repeatedly across Swiss deals, which tells you the ecosystem has structured support behind it, not just opportunistic capital.
- What Drives San Diego's Life Sciences Industry
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Switzerland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio Company develops monoclonal antibody therapeutics for immunological and respiratory diseases | $365M | 1 mo ago | Series B | — | Luca Santarelli Founder | — | — | — | — |
| 2 | MindMaze Therapeutics Developer of neurotherapeutic solutions combining behavior, software, devices, and data | $361M | 0 mo ago | Public | — | Tej Tadi Founder & Co-CEO | WordPressMySQLPHP+29 | — | — | — |
| 3 | CeQur Developer of wearable insulin delivery patch | $272M | 17 mo ago | Series D | 95 | Bradley Paddock President & CEO | WordPressMySQLPHP+30 | — | 69 patents Microfluidic drug‑delivery pumps with precise bolus dosing and dose‑tracking capabilities | 1 launch |
| 4 | SkyCell Provider of temperature-controlled container solutions, monitoring, and ULD tracking services | $270M | 23 mo ago | Series D | 151 | Nico Ros Co-Founder & CTO | HubSpot CMS HubProton MailApple iCloud Mail+18 | 3 signals ▲200% Announcements · New product | — | 1 partnership |
| 5 | Sanoptis Network of eye clinics and practices offering ophthalmological services. | $270M | 14 mo ago | Acquired | 500 | Volker Wendel CEO | WordPressMySQLPHP+20 | — | — | 2 job openings |
| 6 | Distalmotion Developer of robotic devices for surgical procedures 72Funding top 21%Moat top 26%Innovation top 27%Patents top 27% All 11 signals ▾Fundingtop 21% Moattop 26% Innovationtop 27% Patentstop 27% Producttop 34% Talenttop 34% Growthtop 35% Techtop 41% Newstop 45% Marketbottom 48% Globalbottom 42% Funding: Raised $240M across 3 rounds · 3 rounds over 13 yrs (0.2/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 158 patents rank vs industry peers · Fliar Intelligence Index 72/100 | $240M | 5 mo ago | Series G | 126 | Greg Roche CEO | SentryApple iCloud MailGoogle Workspace+17 | — | 158 patents Robotic surgical instrumentation and control systems for minimally invasive procedures | — |
| 7 | Bright Peak Therapeutics Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease | $232M | 25 mo ago | Series C | 57 | Jeffrey Bode Co-Founder | WordPressMySQLPHP+15 | — | 91 patents Engineered cytokine immunocytokines for targeted immune activation in oncology | — |
| 8 | Alentis Therapeutics Developer of therapies for treating fibrosis, cirrhosis, and liver cancer | $184M | 19 mo ago | Series D | 38 | Thomas Baumert Founder & Board Member | WordPressMySQLPHP+19 | 5 signals ▲400% Leadership | 35 patents Bispecific anti‑Claudin‑1/EGFR antibodies for cancer, liver disease and fibrosis therapy | — |
| 9 | Noema Pharma Developer of therapeutic solutions for treating neurological disorders | $172M | 18 mo ago | Series B | 21 | George Garibaldi President and Co-founder - head of Research and Development. | — | — | 80 patents PDE10A inhibitor therapeutics for CNS disorders and metabolic weight‑loss applications | — |
| 10 | Xeltis Developer of bioabsorbable synthetic heart valves and vascular grafts | $164M | 6 mo ago | Series D | 68 | Eliane Schutte Chief Executive Officer | WordPressMySQLPHP+20 | — | 68 patents Bioresorbable electrospun cardiovascular scaffolds for heart valves and vascular grafts. | — |
| 11 | Numab Developer of multispecific antibody therapeutics for inflammation and cancer | $150M | 17 mo ago | Series C | 78 | David Urech CEO | WordPressMySQLPHP+13 | — | 38 patents Engineering bispecific and multispecific antibody formats for therapeutic targeting. | — |
| 12 | Asceneuron Developer of small molecules for the treatment of neurodegenerative diseases | $137M | 23 mo ago | Series C | 3 | — | — | — | 159 patents Novel small‑molecule glycosidase inhibitor chemotypes and their pharmaceutical salts | — |
| 13 | iOnctura Developer of pharmaceuticals to treat cancer | $112M | 23 mo ago | Series B | 20 | Lars van der Veen Founder & CTO | — | 3 signals ▲50% Leadership | 39 patents Patents concentrated in health & consumer products | — |
| 14 | Spineart Developer of orthopedic implants and minimally invasive instruments | $108M | 8 mo ago | Series B | 289 | Stephane Mugnier-Jacob Co-Founder | WordPressApple iCloud MailMicrosoft 365+25 | — | 168 patents Spinal fusion and fixation devices, intervertebral cages, disc prostheses, pedicle instrumentation | — |
| 15 | ImmunOs Therapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $102M | 21 mo ago | Series C | 31 | Christoph Renner Co-Founder & CMO | — | — | 33 patents Engineered HLA fusion proteins targeting CD47‑SIRPA checkpoint for cancer immunotherapy | — |
| 16 | Neo Developer of a surgical instrument for spinal surgeries | $102M | 21 mo ago | Series B | 51 | Vincent Lefauconnier Co-Founder & Co-CEO | WordPressTypeScriptPHP+41 | — | — | 1 launch |
| 17 | Granite Bio Developer of therapeutic antibodies that target inflammatory, autoimmune, and fibrotic conditions | $100M | 13 mo ago | Series B | — | Matthias Mack Founder | Cart FunctionalitySquarespace CommerceSquarespace+17 | — | — | — |
| 18 | Nuclidium Developer of radiopharmaceuticals for the treatment of cancer | $99M | 0 mo ago | Series B | 8 | Leila Jaafar Founder & CEO | WordPressApple iCloud MailMicrosoft 365+27 | — | 41 patents Targeted radiopharmaceuticals for FAP and integrin imaging/therapy using high-purity radionuclides | — |
| 19 | RhyGaze Developer of gene therapies to restore vision | $97M | 17 mo ago | Series A | — | Charles Gubser Co-Founder | PHPGSAPApache HTTP Server+15 | — | — | — |
| 20 | Mosanna Therapeutics Developer of small molecule therapeutics for sleep apnea | $80M | 12 mo ago | Series A | 4 | Jonathan Talbot Co-Founder & CEO | — | — | — | — |
| 21 | CUTISS Company developing personalized skin tissue therapeutics for skin defect treatments | $55M | 9 mo ago | Series C | 50 | Daniela Marino Co-Founder & CEO | — | — | 80 patents Regenerative skin grafts using hydrogel scaffolds and stem cell isolation technologies | — |
| 22 | Corflow Developer of diagnostic and therapeutic solutions for microvascular obstruction | $51M | 21 mo ago | Series B | 12 | Paul Mead CEO | WordPressMySQLPHP+19 | — | — | — |
| 23 | GlycoEra Developer of biologics for selective degradation of disease-driving extracellular proteins | $49M | 12 mo ago | Series B | 29 | — | WordPressMySQLPHP+15 | — | 24 patents Therapeutic glycoengineered biologics for antibody targeting and glycan‑mediated protein degradation | 1 job opening · 1 award |
| 24 | Mabylon Developer of therapeutics for allergies and neurodegenerative diseases | $39M | 10 mo ago | Series B | — | Alcide Barberis CEO | PHPGoogle MapsBootstrap+13 | — | 38 patents Therapeutic antibodies for allergens and ASC-mediated inflammation treatment | — |
| 25 | Sequana Medical Developer of implantable battery-powered pump for removal of ascites | $36M | 15 mo ago | Public | 70 | Ian Crosbie CEO | WordPress Block EditorWordPressPlesk+29 | 7 signals ▲40% Capital raise · Announcements · Funding | 72 patents Implantable therapeutic devices with wireless power and fluid drainage management | 3 launchs |
| 26 | SamanTree Medical Developer of digital microscopy system for high-resolution imaging of tissue | $28M | 4 mo ago | Series C | 25 | Etienne Shaffer CTO & ex-Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+23 | — | 61 patents Fluorescence microscopy reagents and motion‑reduced confocal imaging systems | 2 partnerships |
| 27 | HAYA Therapeutics Developer of RNA-based therapies for treating heart diseases | $25M | 13 mo ago | Series A | 38 | Samir Ounzain Co-Founder & CEO | WordPressMySQLPHP+18 | — | 18 patents RNA‑based therapeutics targeting noncoding RNAs, super‑enhancers, and transposable elements for disease modulation | — |
| 28 | NLS Pharma Developer of small molecule therapeutics for CNS, mental and behavioral disorders | $24M | 11 mo ago | Public | 250 | Eric Jean Desbois NLS Pharmaceutics Co-founder | Vue.jsApache HTTP Servercore-js+4 | 4 signals ▼71% M&A | 26 patents Extended-release mazindol tablet formulations for ADHD treatment | — |
| 29 | Aurealis Therapeutics Developer of cell and gene therapies for chronic wounds and cancer | $22M | 19 mo ago | Series B | 17 | — | WordPressMySQLPHP+21 | — | 10 patents Inducible bacterial expression platforms for therapeutic protein production | 1 job opening |
| 30 | STALICLA Manufacturer of precision medicinea for neurodevelopmental disorders | $22M | 11 mo ago | Series B | 26 | Lynn Durham Founder & CEO | TypeScriptVideoJSZone.js+8 | — | 116 patents Autism therapeutics, diagnostics, and biomarker assays for neurodevelopmental disorders | — |
| 31 | Novigenix Developer of technology for cancer precision medicine | $20M | 14 mo ago | Series B | 28 | — | WordPressMySQLPHP+25 | — | 20 patents Predictive biomarkers and assays for cancer immunotherapy response and colorectal neoplasia detection | — |
| 32 | Virometix Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial… | $19M | 7 mo ago | Series C | 15 | Anna Sumeray CEO | — | — | 41 patents Vaccine antigen design and peptide‑based immunogens for pneumococcal and RSV protection | — |
| 33 | Rivia Provider of an AI-powered data analytics platform for clinical trials | $18M | 3 mo ago | Series A | — | Erik Scalfaro Co-Founder & CEO | WebflowVimeoGSAP+13 | 3 signals Funding | — | — |
| 34 | TECregen Developer of ligand-based solutions to restore and preserve thymus function | $13M | 5 mo ago | Seed | — | Ignacio Moraga Co-Founder & Chief Scientific Officer | — | — | — | — |
| 35 | Berlin Heals Developer of a microcurrent device for heart failure treatment. | $12M | 4 mo ago | Series B | 19 19 → 38 (+100%) | Peter Goettel Co-Founder & Co-CEO | GSAPApache HTTP ServerCloudflare+5 | — | 20 patents Implantable segmented DC electrodes for therapeutic organ stimulation and monitoring | — |
| 36 | FoRx Therapeutics Developer of compounds for treating cancer | $11M | 5 mo ago | Series A | 22 | Sotirios Sotiriou Co-Founder | WordPressMySQLPHP+16 | — | 35 patents Small-molecule inhibitors of PARG and WRN enzymes for cancer therapeutics | — |
| 37 | Medyria Developer of technology for endovascular catheter navigation and sensing | $10M | 11 mo ago | Series B | 10 | — | — | — | 26 patents Intravascular catheters with integrated flow sensors for real-time blood velocity measurement | 1 expansion |
| 38 | Positrigo Provider of device for brain imaging | $10M | 12 mo ago | Series C | 17 | Max Ahnen Co-Founder | WordPress Block EditorWordPressPlesk+28 | — | 34 patents PET scanner hardware and patient positioning systems for improved imaging efficiency | 1 partnership · 1 award |
| 39 | Odne Developer of medical devices for root canal treatment | $9M | 12 mo ago | Series A | — | Mark Bispinghoff COO & Co-founder | WordPress Block EditorElementorWordPress+35 | — | 13 patents Dental restorative materials and endodontic delivery devices with high radiopacity and precision | — |
| 40 | arcoris bio Developer of nanotechnology reagents and protocols for RNA and protein detection | $8M | 7 mo ago | Seed | — | Scott Fraser Co-Founder | — | — | — | — |
| 41 | Comphya Developer of a neurostimulator implant for treating male impotence | $6M | 11 mo ago | Series A | 6 | Rodrigo Fraga-Silva Co-Founder & COO | — | — | 10 patents Neuromodulation devices for pelvic floor and sexual dysfunction therapy | 1 launch |
| 42 | Curatis AG Swiss specialty Pharma company focussed on rare diseases and specialty care | $5M | 0 mo ago | Public | — | Gunter Graubach Founder | WordPressMySQLPHP+11 | — | 7 patents Repurposed pharmaceutical agents for migraine and medication‑overuse headache treatment | — |
| 43 | AlitheaGenomics Provider of transcriptomics solutions for research and biomarker discovery 37Talent top 38%Funding top 42%Tech top 42%News top 43% All 8 signals ▾Talenttop 38% Fundingtop 42% Techtop 42% Newstop 43% Growthtop 45% Moattop 48% Globalbottom 39% Marketbottom 26% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $4M | 3 mo ago | Seed | 9 | Daniel Alpern Co-Founder | WordPressApple iCloud MailMicrosoft 365+30 | — | — | 2 launchs · 1 partnership |
| 44 | Allegria Therapeutics Developer of therapeutics for allergy and inflammatory diseases | $4M | 6 mo ago | Seed | — | Maria Van Dongen Chief Executive Officer & Co-founder | — | — | — | — |
| 45 | Moonlight AI AI-powered diagnostics platform that democratizes access to genomic information for cancer diagnostics | $3M | 1 mo ago | Seed | 4 | Sezai Taskin Co-Founder & CEO | Wix eCommerceWixSentry+12 | — | — | 1 job opening · 1 award |
| 46 | Rhovica Developer of an external ventricular drain to decrease intracranial pressure | $3M | 9 mo ago | Seed | — | Martin Hlavica Co-Founder | — | — | — | — |
| 47 | EarlySight Provider of retinal imaging solutions for retinal disorders | $3M | 9 mo ago | Seed | 11 | Francine Behar-Cohen Co-Founder | WordPressMySQLPHP+20 | — | 6 patents Non‑invasive transscleral optical imaging and AI‑driven retinal diagnostics. | — |
| 48 | Oncobit Developer of diagnostic and monitoring tests for precision treatment | $3M | 6 mo ago | Series A | 13 | Claudia Scheckel CEO | — | — | 2 patents Detecting specific DNA/RNA mutations in clinical samples using computational analysis | 1 launch |
| 49 | Babylat Developer of an automated device for enriching human milk protein and fat. | $996K | 4 mo ago | Funding Raised | 3 | — | — | — | 11 patents Fortified infant milk formulation and protein enrichment technologies for human breast milk | 1 partnership |
| 50 | Neurosoft Bioelectronics Provider of soft implantable electrodes for neurological disorders | $208K | 0 mo ago | Seed | 7 | Nicolas Vachicouras Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | — | 1 award |
Top 12 Life Sciences companies in Switzerland
#1
Public · Lausanne, Vaud · founded 2012$360.6Mraised▾
Developer of neurotherapeutic solutions combining behavior, software, devices, and data. The company offers a platform for brain health and recovery. It provides precision neurotherapeutics through a portfolio of solutions. The company also develops formulations for rare diseases. Its offerings include an immersive experience platform for brain recovery and a neurorehabilitation system. It provides a hand training peripheral and technology for digital motion assessments.
- Feb 2022Series B$105M
- Feb 2022Grant (prize money)$12.1M
- Oct 2021Conventional Debt$125M
- Sep 2017Angel—
#2
Series B · Basel, Basel Stadt · founded 2020$365Mraised▾
Company develops monoclonal antibody therapeutics for immunological and respiratory diseases. It focuses on advancing a thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development. It also creates novel, long-acting bispecific programs for immunological diseases. The company's lead candidate, WIN378, is a fully human monoclonal antibody engineered for extended half-life and effector silencing, targeting the TSLP ligand to treat asthma, COPD, and other inflammatory phenotypes.
- May 2026Series B$165M
- Jan 2025Series A$200M
#3
Series B · Basel, Basel Stadt · founded 2017 · 8 employees$99Mraised▾
Developer of radiopharmaceuticals for the treatment of cancer. The company is developing copper-based therapeutics and companion diagnostics which include NuriPro for Prostate cancer, TraceNET for Neuroendocrine tumors (NET), and CuNeo for Colorectal, Gastric & lobular breast cancer.
- Jul 2025Series B$99M
#4
Series G · Epalinges, Vaud · founded 2012 · 126 employees$240Mraised▾
Developer of robotic devices for surgical procedures. It develops DEXTER, a hybrid surgical robot that simplifies robotic-assisted minimally invasive surgery for hospitals and outpatient settings. It consists of fully articulated, single-use 8 mm instruments for suturing and dissection, like needle drivers, Johann graspers, monopolar scissors, and bipolar Maryland forceps. The device also provides the option to switch between laparoscopic and robotic surgery at any time during surgery.
- Jan 2026Series G—
- Nov 2025Series G$150M
- Sep 2024Series F—
- Apr 2023Series F$150M
#5
Series D · Zurich, Zurich · founded 2006 · 68 employees$164.4Mraised▾
Developer of bioabsorbable synthetic heart valves and vascular grafts. The implants function as natural valves and vessels, allowing the body to heal. As the matrix gets absorbed over time, components of native tissue develop into functioning natural tissue. The flagship product is a replacement pulmonary valve for children with congenital heart malformations.
- Dec 2025Venture Debt$43.6M
- Dec 2025Series D$11.6M
- Aug 2023Series D$13.7M
- Feb 2023Series D$34.2M
#6
Series C · Lausanne, Vaud · founded 2014 · 25 employees$27.8Mraised▾
Developer of digital microscopy system for high-resolution imaging of tissue. The system allows rapid imaging of fresh tissue surfaces without slicing. It uses confocal microscopy for tissue visualization while preserving the specimen. The system includes a fluorescent stain and single-use device for imaging. Digital tools allow physicians to review images remotely and annotate areas of interest.
- Jan 2026Series C$23.7M
- Apr 2025Series B$6M
- Jul 2024Series B$14M
- Aug 2021Grant (prize money)$59K
#7
Series B · Plan les Ouates, Geneva · founded 2005 · 289 employees$108Mraised▾
Spineart is a developer of patented minimally invasive surgical instruments and orthopedic implants for spinal or other orthopedic surgeries. It offers a portfolio of implants includes cervical cages, fixation implants, posterior Ti cages, lateral Ti cages, interspinal fusion device and many more. The instruments are used for arthroplasty, cervical fixation, deformity, interbody fusion, and thoracolumbar fixation. Some of the products have received FDA clearance.
- Sep 2025Series B$31.3M
- Mar 2024Convertible Debt$22.5M
- Jun 2020Series B$52M
- Sep 2016Series A$33.5M
#8
Series A · Switzerland · founded 2002$18.2Mraised▾
Provider of an AI-powered data analytics platform for clinical trials. It integrates fragmented trial data from various sources into a standardized format, enabling real-time access and analysis. The platform offers visual intelligence tools and AI-powered conversational agents to facilitate data exploration and interpretation, streamlining clinical operations, safety monitoring, and executive oversight.
- Mar 2026Series A$15M
- Jun 2024Seed$3.2M
#9
Series C · Zurich, Zurich · founded 2017 · 50 employees$55.4Mraised▾
Company developing personalized skin tissue therapeutics for skin defect treatments. The company is pioneering a novel approach to personalized skin treatment, leveraging its proprietary technology to create customized skin grafts for various medical applications. With a strong foundation in regenerative medicine and tissue engineering, CUTISS aims to revolutionize skin surgery and improve patient outcomes.
- Sep 2025Series C$39M
- May 2024Series C$27.5M
- Jan 2022Grant (prize money)$339.6K
- Dec 2020Grant (prize money)$61.4K
#10
Public · Basel, Basel Stadt · founded 2002$5.3Mraised▾
Curatis AG is a developer of therapeutics for rare diseases. The products developed are antitoxins (cyanide and digoxin) for chorea associated with Huntington's disease and interstitial cystitis. The product pipeline includes products in phase II (episodic headaches, and migraines with aura) and one in preclinical for WABB (Wolfram syndrome, Alström syndrome, Bardet-Biedl syndrome).
- May 2026Post IPO$3.8M
- Nov 2025Post IPO$1.5M
#11
Series B · Zug, Canton of Zug · founded 2010 · 19 employees$11.9Mraised▾
{}
- Feb 2026Series B$10M
- Sep 2025Series A$5M
- Feb 2025Series A$7.8M
- Jun 2023Series A$6.7M
#12
Acquired · Zug, Canton of Zug · founded 2018 · 500 employees$269.9Mraised▾
Network of eye clinics and practices offering ophthalmological services. It provides a platform for modern eye clinics and practices. The company facilitates collaborations, investments, and training for improved patient care. It fosters knowledge sharing among medical professionals. The company supports recruitment and development of medical staff. It advises clinics and practices on optimizing operations, personnel, finance, and marketing. The company invests in equipment and facilities to ensure treatment in a comfortable environment.
- Mar 2025PE$269.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Switzerland
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 469 Switzerland-affiliated papers.
- ETH Zurich52
- University of Zurich40
- University of Lausanne34
- Agroscope30
- University of Basel30
- Gene2→9
- Chromatin1→8
- Antibody3→7
- Epitope1→5
- Immune system1→4
- Population2→4
- Antimicrobial1→5
- Context (archaeology)1→4
- Agriculture2→4
Where biotechnology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.